天美传媒

Biography

Lanhai Lü, PhD Research Associate Room 263C, Department of Oral Immunology and Infectious Diseases School of Dentistry University of Louisville 501 S. Preston St. Louisville, KY 40202 Tel: 502-804-6394(Cell) Email: lhlv6387@hotmail.com

Research Interest

Curent research interests Oral cancer (OC) is one of the most common cancers in the world脙炉脗录脜聮which accounts for about 4% of all cancer cases. Although treatments have greatly improved in the past few years, the survival rate in patients with advanced OSCC treated by surgery alone or radiotherapy alone is still poor. Chemotherapy together with surgery or radiotherapy was an effective therapy in advanced OSCC, but the effectiveness is limited by chemoresistance to certain anticancer drugs. Cisplatin has been used to treat OSCC for many years. But it often failed in some cases. The molecular mechanisms of cisplatin drug resistance remains largely known. Our present study focus on the effects of cisplatin on 脙掳脗聺芒聙潞脗陆-catenin, the main regulator in Wnt signaling pathway. The data shown overexpression of 脙掳脗聺芒聙潞脗陆-catenin could enhanced cisplatin resistance in OSCC cell lines, indicating 脙掳脗聺芒聙潞脗陆-catenin may play a crucial role in the development of drug resistance in OSCC(Biomed Res Int. 2016;2016:5378567.). β-catenin is a target for the ubiquitin-proteasome pathway. We also study the effects of FDA approved drug Bortezomib and another proteasome inhibitor MG132 on E-cadherin/β-catenin complex. Our data shown MG132 or bortezomib alone induced remarkable loss of cell integrity and contact, disrupted E-cadherin/β-catenin complex which could contribute to overcoming the multidrug resistance of oral cancer (Toxicol In Vitro. 2015 ;29(8):1965-76.).